Holen Sie sich die Stockscreener-App
3.50
5.42%
0.18
Handel nachbörslich:
3.47
-0.03
-0.86%
Schlusskurs vom Vortag:
$3.32
Offen:
$3.38
24-Stunden-Volumen:
446.28K
Relative Volume:
0.73
Marktkapitalisierung:
$44.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.12M
KGV:
-2.2294
EPS:
-1.5699
Netto-Cashflow:
$-15.68M
1W Leistung:
+11.46%
1M Leistung:
+30.60%
6M Leistung:
+15.89%
1J Leistung:
+4.48%
1-Tages-Spanne:
$3.335
$3.60
1-Wochen-Bereich:
$2.825
$3.60
52-Wochen-Spanne:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.50 | 42.36M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com
Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace
Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus
Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com Australia
Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC - TradingView
About Us - FinancialContent
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Rev - GuruFocus
Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History - Benzinga
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
Lantern Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bios funds report 4.48% Lantern Pharma (NASDAQ: LTRN) stake - Stock Titan
Lantern Pharma (NASDAQ: LTRN) cuts R&D, advances oncology pipeline and AI spin-out - Stock Titan
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout - Stock Titan
Lantern Pharma Sees Funding Sufficient Until Mid-1Q27 >LTRN - Moomoo
Lantern Pharma Releases Q1 2025 Financial Results - AlphaStreet
Lantern Pharma Announces $9.25 Million Registered Direct Offering and Plans for Independent AI Entity with withZeta.ai 1 - Minichart
Lantern Pharma closes $4.4M registered direct offering By Investing.com - Investing.com Australia
Why is Lantern Pharma stock soaring Monday? - MSN
Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph - GuruFocus
Lantern Pharma raises capital, plans AI platform spinoff - TipRanks
Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw - TradingView
Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out - Stock Titan
Lantern Pharma closes $4.4M registered direct offering - Investing.com
Lantern Pharma (LTRN) director buys shares and long-dated warrants - Stock Titan
Lantern Pharma (LTRN) director adds shares and long-dated stock warrants - Stock Titan
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) sells 1.45M shares, pre-funded warrants included - Stock Titan
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - BioSpace
Lantern Pharma Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Lantern Pharma raises $4.4M in registered direct offering - Investing.com UK
Lantern Pharma Inc. announces up to $9.25 million registered direct offering with existing holders and a single institutional investor - marketscreener.com
Lantern Pharma raises $4.4M in registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - BioSpace
Lantern Pharma (LTRN.US) will release its earnings report after the market closes on May 15. - Moomoo
Press Release: Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - Moomoo
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08Wall Street Picks - newser.com
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
Lantern Pharma Inc. Unveils Roadmap for Withzeta.Ai with Launch of Zetaswarm and Zetaomics - marketscreener.com
Lantern Pharma Inc. 2025 Annual Report Amendment – Executive Compensation, Corporate Governance, and Audit Committee Details - Minichart
Lantern Pharma (NASDAQ: LTRN) details pay, ownership, options - Stock Titan
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery - MEXC Exchange
Lantern Pharma (LTRN) Introduces Advanced Molecular Intelligence Platform - GuruFocus
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Glob - Business Wire
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):